Binding molecules specific for CD73 and uses thereof

Patent metadata

Field	Value
Publication number	US-11525012-B2
Application number	US-201916678165-A
Country	US
Kind code	B2
Filing date	Nov 8, 2019
Priority date	Nov 10, 2014
Publication date	Dec 13, 2022
Grant date	Dec 13, 2022

Abstract

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

First claim

What is claimed is:

1. An isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 having an antibody VL and an antibody VH comprising VL-CDR1, VL-CDR2, VL-CDR3, VH-CDR1, VH-CDR2, and VH-CDR3, wherein VL-CDR1 comprises SEQ ID NO: 46, VL-CDR2 comprises SEQ ID NO: 51, VL-CDR3 comprises SEQ ID NO: 56, VH-CDR1 comprises SEQ ID NO: 36, VH-CDR2 comprises SEQ ID NO: 39, and VH-CDR3 comprises SEQ ID NO: 45, which specifically binds to an epitope of a CD73 protein comprising one or more amino acids corresponding to Val144, Lys180, and Asn185.

2. The isolated binding molecule or antigen-binding fragment thereof, of claim 1 , further comprising one or more amino acids corresponding to Tyr135, Lys136, and Asn187.

3. The isolated binding molecule or antigen-binding fragment thereof, of claim 1 , comprising the amino acids corresponding to Tyr135, Lys136, and Asn187.

4. The isolated binding molecule or antigen-binding fragment thereof, of claim 1 , comprising the amino acids corresponding to Tyr135, Lys136, Asn185, Tyr135, Lys136, and Asn187.

5. The isolated binding molecule or antigen-binding fragment thereof, of claim 1 , which binds an epitope within one or more of the following regions of a CD73 protein: Tyr132-Val144 or Lys180-Asn187.

6. The isolated binding molecule or antigen-binding fragment thereof, of claim 1 , comprising the amino acid sequences at Tyr132-Val144 or Lys180-Asn187.

Assignees

• Medimmune Ltd

Inventors

• Hay Carl
• Sachsenmeier Kris
• Sult Erin
• Huang Qihui
• Pavlik Peter
• Damschroder Melissa
• Cheng Li
• Diedrich Gundo
• Rios-Doria Jonathan
• Hammond Scott
• Minter Ralph
• Rust Steve
• Guillard Sandrine
• Hollingsworth Robert
• Jermutus Lutz
• Durham Nicholas
• Leow Ching Ching
• Antonysamy Mary
• Geoghegan James
• Lu Xiaojun
• Rosenthal Kim

Classifications

• C07K16/2818

  against CD28 or CD152 · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title